The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.

A synergistic, multi-factor hair growth formulation and its method of use are described. A plurality of synthetic peptides and proteins are selected to maximize efficacy at discrete stages of the anagenic growth phase of a hair follicle, and these compounds may be further coated to promote uptake into the skin and/or hair root. The formulation itself is topical, so as to allow for direct, selective application alone or in combination with mechanical or energetic delivery techniques.

The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analog formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.

A method of activating inactive hair follicles by administering a composition including an effective amount of zinc thymulin to a subject. The method generates new hair growth and may be used to treat or prevent hair loss or, alternatively, to increase the quantity of hair in a subject that does not suffer from hair loss.

The present invention relates to methods of treating blepharitis and dry eye by inhibiting the binding ability of lid flora bacteria such as Staphylococcus aureus and Staphylococcus epidermidis, thus inhibiting biofilm formation and the increase in bacterial populations and densities that lead to quorum-sensing-gene activation and therefore, the production of inflammatory virulence factors.

Disclosed herein are contractile cell constructs comprising contractile cells, or progenitors thereof, adhered to a surface of a three dimensional fibroblast containing scaffold (3DFCS) and methods for using them to treat disease. In one aspect, the present invention provides methods for preparing a contractile construct, comprising (a) seeding immature contractile cells onto the surface of a three dimensional fibroblast containing scaffold (3DFCS) to produce a contractile construct; and (b) culturing the contractile construct under conditions to promote differentiation of the immature contractile cells into mature contractile cells, wherein the mature contractile cells form striations. In a further aspect, the invention provides methods for treating a disorder characterized by a lack of functioning contractile cells, comprising contacting a patient with a contractile cell-based disorder with an amount effective to treat the disorder with the construct of any embodiment or combination of embodiments of the invention.

Disclosed herein are contractile cell constructs comprising contractile cells, or progenitors thereof, adhered to a surface of a three dimensional fibroblast containing scaffold (3DFCS) and methods for using them to treat disease. In one aspect, the present invention provides methods for preparing a contractile construct, comprising (a) seeding immature contractile cells onto the surface of a three dimensional fibroblast containing scaffold (3DFCS) to produce a contractile construct; and (b) culturing the contractile construct under conditions to promote differentiation of the immature contractile cells into mature contractile cells, wherein the mature contractile cells form striations. In a further aspect, the invention provides methods for treating a disorder characterized by a lack of functioning contractile cells, comprising contacting a patient with a contractile cell-based disorder with an amount effective to treat the disorder with the construct of any embodiment or combination of embodiments of the invention.

The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T4. The preparation according to the present invention provides T4 in a stable state by maintaining the biological activity of T4 and minimizing the generation of T4 sulfoxide through oxidization reactions and multimers through aggregation.

The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis receptor (HusTNFR) and belongs to the gene engineering technology and gene function application field. This invention uses type I or type II long-acting HusTNFR (LHusTNFR) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models. The results showed that LHusTNFR, which has a half-life of 12-140 hours, shows excellent efficacy for preventing the development of severe liver injury on chronic liver disease and for treating early-stage severe liver injury on chronic liver disease. It also significantly reduced the mortality of the model animals. Its efficacy for the prevention and treatment of early-stage severe liver injury on chronic liver disease was significantly better than that of non-LHusTNFR.